stock meeting

CVOs vs. CROs

Greater control. Better outcomes.

A contract vivarium (CVO) offers a strategic alternative to CRO outsourcing, enabling biotech teams to run studies in-house with greater control, faster timelines, and stronger confidence in their data.


Why Study Control Matters in Early Development

Early-stage in vivo research plays a critical role in determining whether therapeutic programs advance or fail. Across therapeutic areas and emerging modalities, experimental design, protocol adjustments, and real-time observation are essential to generating reliable proof-of-concept and translational data.

The contract vivarium model allows research teams to maintain direct oversight of experimental design and execution while operating within professionally managed facilities that provide animal care, veterinary services, and regulatory compliance.

procedure2

The CVO approach enables companies to conduct their own non-GLP rodent studies supporting:

  • Target validation and mechanism-of-action research
  • In vivo pharmacology, PK/PD, and dose-ranging studies
  • Early efficacy and disease model evaluation
  • Translational studies informing downstream development decisions
  • Iterative experimental design and protocol refinement

Contract Vivarium vs. CRO Outsourcing

For many biotech companies, CRO outsourcing has been the traditional path for preclinical in vivo studies. However, CRO service models often operate within fixed timelines and standardized workflows across multiple clients.

While CROs remain valuable for regulated and specialized studies, many discovery and proof-of-concept programs benefit from environments where scientists maintain direct involvement in study execution and interpretation. The contract vivarium model enables research teams to conduct studies within controlled facilities while avoiding common limitations of outsourced research pipelines.

Feature Contract Vivarium Model Traditional CRO Model
Study Execution Scientists conduct and oversee their own studies Studies executed by external CRO teams
Flexibility to Pivot Immediate protocol adjustments and study iteration Changes often require study redesign or contract amendments
Hands-On Study Management Continuous observation of animal models Limited direct interaction with studies
Control of Timelines Research schedules controlled by the internal team Study timelines dependent on CRO availability
Expertise in Proprietary Study Designs Direct handling of proprietary or novel research programs Standardized CRO workflows may limit expertise
Contract Vivarium Model Traditional CRO Model
Study Execution Scientists conduct and oversee their own studies Studies executed by external CRO teams
Flexibility to Pivot Immediate protocol adjustments and study iteration Changes often require study redesign or contract amendments
Hands-On Study Management Continuous observation of animal models Limited direct interaction with studies
Control of Timelines Research schedules controlled by the internal team Study timelines dependent on CRO availability
Expertise in Proprietary Study Designs Direct handling of proprietary or novel research programs Standardized CRO workflows may limit expertise

Data That Withstands Scientific and Investor Diligence

The standards for early-stage proof-of-concept data have shifted. Venture investors and pharmaceutical partners increasingly require robust in vivo datasets before advancing programs into licensing discussions, Series B financings, or clinical development.

Data generated within contract vivarium environments allows scientific teams to remain directly involved in study execution, observation, and interpretation. This level of engagement strengthens experimental rigor and ensures that critical variables, protocol adjustments, and model behavior are understood in real time.

As a result, companies can develop data packages that support:

  • Scientific reproducibility and internal validation
  • Investor and pharmaceutical diligence review
  • Mechanistic interpretation of study outcomes
  • Clear attribution of experimental variables and study conditions
  • Confident progression into IND-enabling development

Mispro vs. CRO

  • 6X Increase in study throughput
  • 50% Less spend over time
  • 70% Reduction in failure rates

Exit Activity Across Mispro Vivaria

  • 75% Of biotech M&A activity in 2025
  • $19B In 2025 M&A value
  • 25% Achieved exits since 2018

Find Lab Space Near You

Explore Our Network of Full-Service In Vivo Lab Facilities Near You

Find Your Location

Ready to Get Started?

Connect with a Mispro representative to discuss your vivarium needs.